

Use of Caffeine Citrate for Apnea of Prematurity









KEMRI Wellcome Trust

Objectives


- 1. Define apnea and Apnea of Prematurity.
- 2. Discuss the pathophysiology of AoP.
- 3. Outline the treatment and prevention of AoP
- 4. Discuss mechanism of action of caffeine and its adverse effects.

5. Define how to monitor patient at risk and on treatment for AoP



Introduction

Definitions



Apnea:

- -Cessation of breathing in a premature infant for 20 s or longer
- -Shorter pause accompanied by bradycardia (<100 bpm), cyanosis or pallor



Periodic breathing:

- -Pattern of regular breathing alternating with pauses in respiration of at least 3 seconds, persisting through at least three cycles of breathing.
- -Less than 20 sec
- -Not associated with bradycardia nor hypoxemia



Types of Apnea

Central apnoea: 40%

- Caused by decreased CNS stimuli to respiratory muscles.
- Respiratory effort and airflow cease simultaneously.
- ✓ Absence of chest wall movement and airflow.

Mixed apnoea: 50%

- √Has a mixed aetiology.
- ✓ Central apnoea is either preceded (usually) or followed by obstructed respiratory effort.

Obstructive apnoea: 10%

- Caused by pharyngeal instability, neck flexion or nasal obstruction.
- ✓ Absence of airflow in presence of inspiratory efforts.
- There is presence of chest wall movement but no airflow.



Causes of apnea

- ☐ Hypoglycemia
- Hypothermia
- Anemia
- Sepsis

Apnea of prematurity (AOP)

- ☐ Diagnosis of exclusion.
- ☐ Other causes of apnea must be ruled out



Risk factors for apnea

1. Prematurity - AoP

2.Secondary causes

- A. Central nervous causes (seizures, intracranial hemorrhage, hypothermia, depressant drugs)
- **B. Pulmonary causes** (pneumonia especially due to RSV, laryngeal reflex, vocal cord paralysis, pneumothorax, tracheal occlusion by neck flexion)
- C. Sepsis
- **D. Metabolic causes** (hypoglycemia, hypocalcemia, hyponatremia, and hypernatremia)
- E. Anemia.




Apnea of Prematurity

Epidemiology of apnea of prematurity



AOP is inversely related to gestational age and birth weight.



Newborns born <34 weeks GA are at risk for Apnea of Prematurity!



Neonatal breathing - Chemosensitivity

Central
chemosensitivity to
high CO₂ is
diminished in preterm
infants, and this
relative "insensitivity"
is directly proportional
to the level of
prematurity.



Central chemoreceptors:

-Located in the in the brain


High CO₂ and acidosis in extracellular fluid

Activation results in increased respiratory rate and depth



Neonatal breathing – Biphasic response to hypoxia

Effect of maturation on hypoxic ventilatory responses 300 Minute Ventilation % of Control Adult Prehypoxic control level Premature infant 10 12 Time (min) Hypoxic gas challenge





Prevention and Treatment of Apnea of Prematurity for preterms born at < 34 weeks gestation age

Supportive care important in care of premature neonates

- Get the basics right!
- 1. Stabilization Newborn resuscitation where required.
- 2. Keep warm to maintain body temp 36.5-37.5°C
- 3. Initiate CPAP/oxygen as per hospital policy.
- 4. Feed within the first ONE hour of birth thus establish IV access and/or Nasal or Oral gastric tube as indicated.
- 5. Adequate history and systemic examination should be done.

-Assess gestation:

- 1. By dates from LNMP (Accuracy not assured)
- 2. Obstetric ultrasound (?taken before 15 weeks gestation)
- 3. Ballard score done on day of birth. (Unreliable >4 days old)



Treatment strategies



Exclude and treat for other causes of apnea eg hypothermia, hypoglycemia.



Pharmacological therapy – Methylxanthines



Non-pharmacological therapies:

- -Nasal CPAP
- -Heated humidified high flow nasal cannula (HHFNC)
- -Nasal intermittent positive pressure ventilation (NIPPV)



Methylxanthines

Examples

- 1. Caffeine citrate
- 2. Aminophylline

√They activate the respiratory centers and increase CO₂ sensitivity

Action

- ✓Induce bronchodilation
- Enhance diaphragmatic function

Above result in improved respiratory response to hypoxia and increased CO₂




Caffeine citrate

Why is caffeine citrate preferred?



Fewer side effects

Wider therapeutic index



Longer elimination half-life that allows once-daily dosing

-Caffeine is as effective as aminophylline BUT is **safer** and **easier** to administer and has better therapeutic properties.

It is therefore preferred for the treatment of apnea of prematurity.

Pharmacokinetics of caffeine citrate

Distribution of caffeine in the body:

- Hydrophobic and distributed evenly in all body fluids without tissue accumulation.
- It is highly lipid-soluble and crosses all biological membranes, including the blood-brain-barrier.

Metabolism and excretion:

- Metabolism of caffeine occurs primarily in the liver.
- In neonates, approximately 85% of caffeine is excreted unchanged in the urine compared to <2% in adults.

Caution to be taken for newborns with renal or hepatic disease



Pharmacokinetics of caffeine citrate

Half life:

- Serum half-life of caffeine in preterm infants is prolonged more than ten times that of adults because of immature hepatic metabolism and renal excretion
- Mean half life is 100 hours in preterms.
- -Once a day dose is adequate
- -Upon stopping the medication continue monitoring of adverse effects up to 7 days.
- -There is no requirement for dose tapering on cessation of treatment.



Route of administration for caffeine citrate

- Pharmacokinetics of caffeine is largely <u>independent</u> of the route of administration.
- Oral caffeine:

This oral route preferred unless there are contraindications of enteral feeds. Caffeine is compatible with breastmilk(EBM). 10%D, N/S, KCI

- IV caffeine citrate:
 - Prophylactic loading dose is given slowly over 30minutes. This achieves effect not very different from oral dosing.

Timing of caffeine citrate therapy

Rescue versus prophylactic caffeine citrate treatment?

Prophylactic caffeine recommended as it is associated with:

- 1. Decreased duration of oxygen therapy
- 2. Decreased duration of invasive and noninvasive ventilation
- 3. Decreased incidences of mild to moderate Bronchopulmonary Dysplasia.
- 4. Less need for Patent Ductus Arteriosus (PDA) treatment
- 5. Reduced severity of retinopathy of prematurity (ROP)
- Improved survival rates without neurodevelopmental disability at 18–21 months age.
- Decreased hospital length of stay in preterm infants.

Long J-Y, Guo H-L, He X, Hu Y-H,Xia Y, Cheng R, Ding X-S, Chen F and Xu J (2021) Caffeine for the Pharmacological Treatment of Apnea of Prematurity in the NICU:

Dose Selection Conundrum, therapeutic Drug Monitoring and Genetic Factors. Front. Pharmacol. 12:681842. doi: 10.3389/fphar.2021.681842

Elmowafi M, Mohsen N, Nour I, Nasef N. Prophylactic versus therapeutic caffeine for apnea of prematurity: a randomized controlled trial [published online ahead of print, 2021 Mar 26]. J Matern Fetal Neonatal Med. 2021;1-9. doi:10.1080/14767058.2021.1904873



Dose of Caffeine Citrate – Loading dose

Stable newborn:

 Oral Caffeine citrate 20mg/kg as a loading dose via Nasal or Oral gastric tube within first 4hrs of birth (or first contact for <10 days old)

Unstable newborn: (convulsions, unconscious, severe chest wall in drawing or absent bowel sounds)

- Oral Caffeine citrate 20mg/kg as a loading dose via Nasal or Oral gastric tube given with the first or second trophic feed OR
- IV Caffeine citrate 20mg/kg as a loading dose over 30min.

What is trophic feeds?

- Small volume, hypo-caloric feeding for gut priming or minimal enteral feeding to acclimate the immature gut of enteral fasting preterm neonates.
- Expressed breast milk. NEVER FORMULA
- 1–2 mL/kg/dose or 10-15ml/kg/day
- Early trophic feeds are given within 24 hours of birth.
- Benefits:
 - More energy intake, improved feeding tolerance, greater and faster weight gain and head growth, less sepsis, significantly fewer days of parenteral nutrition and oxygen supplementation, and consequently earlier discharge.



Loading dose of caffeine citrate – worked example.

1.4kg stable neonate:

- 20mg/kg oral caffeine citrate
- We give 28mg
- 20 mg/ml = 1.4 ml.

1.4kg unstable neonate:

- 20mg/kg caffeine = 28mg
- 20mg/ml =1.4ml
- 10mg/ml = 2.8ml
- Oral or slow IV
- Need to top up volume for syringe pump!

A preterm baby 1.4kg would get 80ml*1.4kg =112 ml/24hrs = 4.6mls every hr Approx 1.5ml given in 20 minutes

-Effect of this volume as a bolus???
-Hemodynamic effect of rapid bolus caffeine citrate???



Dose of caffeine citrate – maintenance dose

 Oral Caffeine 5mg/kg via NGT/oral tube starting from 24th hour after the loading dose and then every 24hours.

- If apnea is recorded on treatment:
 - Increase Caffeine maintenance dose to 10mg/kg via Nasal or Oral gastric tube.



Higher doses of Caffeine Citrate?

- 1. Loading dose 40mg/kg and maintenance 20mg/kg:
 - ✓ Better therapeutic effect but significant increase in tachycardia episodes.
 - ✓ No data on the long term effects.
- 2. Loading dose 80mg/kg:
 - ✓Increased incidence cerebellar hemorrhage
 - ✓Increased seizure incidence
- Therapeutic drug levels 8 20mg/L
- Toxic levels >50mg/L
- Routine drug monitoring at standard doses not recommended as caffeine citrate has a wide therapeutic index.

Monitoring patient on treatment



-No need for routine therapeutic drug monitoring on standard doses of caffeine citrate.



- -CONTINUOUS MONITORING of SpO₂, HR, RR
- -Monitoring of vital signs watch out for tachycardia
- -CHANGE oximeter probe site every 4 hours to prevent skin injury
- -Stop continuous monitoring if no episodes of apnoea for 5 7 days without caffeine.



-Observe clinical response

- -Practioners are required to recognize an alarm within 30seconds and respond within 1minute of the alarm sounding.
- -Baby is growing so need to adjust dose regularly every week.



Stopping caffeine citrate



- ✓ Stop caffeine when newborn is **34 weeks post**menstrual age
- ✓ MUST be apnea free for 48hrs before discontinuing caffeine
- -Continue continuous monitoring the newborn for 5-7 days after stopping caffeine.



If apnea recurs after stopping caffeine restart the caffeine citrate – similar dose to the previous dose!

Because of the slow elimination of caffeine in this patient population, there is no requirement for dose tapering on cessation of treatment.



Non-respiratory effects of caffeine citrate

- Receptors through which caffeine acts are present throughout the body.
- Cardiac muscle:
 - Increase heart rate and strength of contraction of heart muscle.
 - Predisposition to arrhythmias and tachycardia

Avoid in symptomatic heart disease

Monitor heart rate and withhold if HR> 180bpm

- · CNS:
 - Reduced seizure threshold

Avoid in patients with kernicterus

Use with caution in patients with seizures




Side effects of caffeine citrate



Increased metabolic rate - may lead to transient slowing of physical growth in the first 3 weeks after starting caffeine



Tachycardia
Consider withholding dose if HR >180bpm at rest



Irritability

All hospitals should have a system for pharmacovigilance in place to register and report any suspected adverse effects!

Long term safety after use of caffeine for apnea of prematurity to the immature brain.



- Improved abilities at age 11 years:
 - Neurobehavioural abilities eg catching a ball, tying laces, solving puzzles.



- Not adversely affected:
 - General intelligence
 - Attention
 - Behavior



Administering caffeine citrate.

 Caffeine is compatible with breastmilk, dextrose solution, KCL, normal saline and PPN

- Caffeine citrate vials are single patient vial; for individual patient needs.
 - Discard unused drug There is high risk of contamination as it has no antimicrobial preservative. Aseptic procedures should be used during the preparation of the loading dose especially IV.
- Caffeine citrate does not require any dilution.



Point of caution on drug interaction with caffeine citrate.

- Caution when used with:
 - Adenosine possible decreased therapeutic effect of adenosine.
 - Cimetidine monitor for caffeine toxicity as cimetidine decreases caffeine clearance.

 Clonazepam - reduced sedative and anxiolytic effects of clonazepam.




Contraindication for use of caffeine citrate

- Contraindications:
 - Kernicterus
 - Symptomatic cardiac disease especially arrhythmias
- Caution while using caffeine citrate in:
 - Renal disease
 - Hepatic disease
 - Seizures



WHO recommendations for care of the preterm or low-birth-weight infant - 2022

- 1. Caffeine is recommended for the treatment of apnoea in preterm infants.
- 2. Caffeine is recommended for the extubation of preterm infants born before 34 weeks' gestation.
- 3. Caffeine may be considered for the prevention of apnoea in preterm infants born before 34 weeks' gestation.




Availability and cost are barriers for the use of caffeine citrate formulations in LMICs

Other therapies for AoP



Tactile stimulation



Kangaroo Mother Care




Blood transfusion.

- -Associated with improved oxygen carrying capacity
- -Conflicting evidence
- -Additional investigation of neurodevelopmental and other long term outcomes needed to decide on liberal versus restrictive transfusion thresholds

Cramer SJE, Dekker J, Dankelman J, Pauws SC, Hooper SB, Te Pas AB. Effect of Tactile Stimulation on Termination and Prevention of Apnea of Prematurity: A Systematic Review. Front Pediatr. 2018;6:45. Published 2018 Mar 2. doi:10.3389/fped.2018.00045



Other therapies for AoP



Gastric acid suppression.

- -Controversial
- -Not sufficient evidence to support a temporal, much less a causal relationship between GER and AoP
- -Harmful effects include increased sepsis, NEC and death
- -Not indicated for the treatment of AOP



Doxapram.

- -Nonspecific CNS stimulant
- -Requires continuous IV infusion
- -Side effects: Hypertension, Tachycardia, Jitteriness, Vomiting, and Low seizure threshold



Planning discharge

- Improvement in occurrence of apnea occurs with increasing age.
- Resolution of apnea happens around 34–36 weeks postmenstrual age.
- Infants born at younger gestations may have persisting symptoms to 40–44 weeks postmenstrual age.
- Infants need to be symptom-free for a period of time prior to discharge
 - CAP suggested 5 days
- There is no data to support use of home electronic surveillance for apnea monitoring.



Questions?

Summary

- Apnea of prematurity is inversely related to gestational age and birth weight.
- All preterm infants at risk of AoP should be initiated on prophylactic caffeine citrate and continuously monitored for occurrence of apnea and adverse effects of caffeine
- Caffeine citrate is the preferred pharmacological agent for prevention and treatment of apnea of prematurity.
- Oral caffeine is preferred for loading and maintenance dose.
- Other standard preterm care strategies are key in caring for preterms with/ at risk of AoP.





NEWBORN ETAT+ TRAINING

Integrating Clinical pathways & procedures with the use of Equipment.

(Incorporating the new WHO recommendations for the care of preterms)

6th-10th February, 2023



University of Nairobi, Kenyatta National Hospital Campus.

Cost of the training:

Ksh 35,000 - East Africans Ksh 30,000 - Students 500\$ - Foreigners Register Here



